UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
Key PointsUBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaround story.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.